HBV-IN-37

CAS No. 380483-01-2

HBV-IN-37( —— )

Catalog No. M37076 CAS No. 380483-01-2

HBV-IN-37 is an HBV inhibitor with an EC50 value of 10 μM and can be used for hepatitis B disease-related research.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 42 In Stock
25MG 70 In Stock
50MG 102 In Stock
100MG 152 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    HBV-IN-37
  • Note
    Research use only, not for human use.
  • Brief Description
    HBV-IN-37 is an HBV inhibitor with an EC50 value of 10 μM and can be used for hepatitis B disease-related research.
  • Description
    HBV-IN-37 is an inhibitor of HBV with an EC50 value of 10 μM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Microbiology/Virology
  • Target
    HBV
  • Recptor
    HBV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    380483-01-2
  • Formula Weight
    439.96
  • Molecular Formula
    C23H22ClN3O2S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(N1C(C=2C(=NN(C2)C3=CC=CC=C3)C4=CC=C(Cl)C=C4)SCC1=O)C5CCCO5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • ?-Thujaplicinol

    ?-Thujaplicinol, a hydroxylated thujaplicinone isolated from western red cedar heartwood, has antiviral activity, inhibits hepatitis B virus replication by blocking viral ribonuclease H activity, and can be used in the study of viral infections.

  • Metacavir

    Metacavir (PNA) is a novel nucleoside reverse transcriptase inhibitor, a deoxyguanosine analog, with anti-hepatitis B virus (HBV) activity and mitochondrial toxicity, which can be used to study HBV infection.

  • BCM-599

    BCM-599 is an efficient HBV capsid assembly inhibitor with in vitro IC50 of 13 uM, shows synergistic inhibitory effects on decreasing viral concentration combined with lamivudine in vivo.